Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Dalvance

    - PMLiVE

    Sanofi patent case win holds off generic rivals for key cancer drug

    Boosts hope of increasing future sales

    - PMLiVE

    Peter Kelly named managing director of Accord Healthcare UK

    He was previously commercial director at Actavis UK

    Eli Lilly HQ

    Lilly wins on appeal in Alimta vitamin regimen dispute

    UK Supreme Court rules in its favour over Actavis

    - PMLiVE

    Teva sells UK and Ireland assets to Intas Pharma for £603m

    Generics portfolio and manufacturing facility gain set to double Indian firm’s UK sales

    Eli Lilly HQ

    UK court backs Actavis in dispute over Lilly’s Alimta

    Actavis’ generic version ruled not to infringe Lilly’s intellectual property

    - PMLiVE

    UK government fines GSK over ‘pay-for-delay’ deals

    Merck KGaA and Actavis also fined for their involvement

    - PMLiVE

    Horizon launches $3bn hostile bid for Depomed

    Horizon wants to add Depomed’s pain therapies and CNS drugs to its products

    - PMLiVE

    Teva planning fresh offer for Mylan, say sources

    Israeli firm has already made multiple informal bids

    - PMLiVE

    Receptos rejected AZ takeover bid, say sources

    Sources also claim the Delaware-based firm is being chased by Gilead Sciences and Teva

    Shire Basingstoke

    Shire rumoured to be pursuing Actelion

    Allegedly made a £12.4bn takeover bid for the Swiss biopharma

    - PMLiVE

    Pfizer ‘bids €1.5bn’ for CAR-T specialist Cellectis

    French immuno-oncology biotech reported to be next on pharma giant's hit list

    - PMLiVE

    FDA approves two new IBS medicines

    US regulator gives the nod to Actavis’ and Salix’ bowel drugs

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links